Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER-2 Positive Breast Cancer × liposomal doxorubicin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 68 Triple Negative Breast Neoplasms 13 Ovarian Neoplasms 7 Neoplasms 6 Neoplasm Metastasis 5 Breast Neoplasms, Male 4 Pancreatic Neoplasms 3 Fallopian Tube Neoplasms 3 Colorectal Neoplasms 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Kidney Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Sezary Syndrome 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms, Plasma Cell 1 Mycosis Fungoides 1 Melanoma 1

Interventions

Trastuzumab 2 liposomal doxorubicin 1 eribulin 1 Metformin 1 Doxorubicin 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡